GenMark Diagnostics (NASDAQ:GNMK) is up 16% premarket on average volume in reaction to its announcement that it has filed an application with the FDA seeking Emergency Use Authorization for its ePlex SARS-CoV-2 Test.
Initial Research Use Only (RUO) tests were shipped
last week to several key customers to validate the assay design using
clinical samples.
https://seekingalpha.com/news/3550499-genmark-files-for-emergency-use-authorization-for-coronavirus-test
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.